<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:46:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8346694" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8346694</identifier>
        <datestamp>2021-08-09</datestamp>
        <setSpec>jncicanspec</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JNCI Cancer Spectr</journal-id>
              <journal-id journal-id-type="iso-abbrev">JNCI Cancer Spectr</journal-id>
              <journal-id journal-id-type="publisher-id">jncics</journal-id>
              <journal-title-group>
                <journal-title>JNCI Cancer Spectrum</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2515-5091</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8346694</article-id>
              <article-id pub-id-type="pmcid">PMC8346694</article-id>
              <article-id pub-id-type="pmc-uid">8346694</article-id>
              <article-id pub-id-type="pmid">34377934</article-id>
              <article-id pub-id-type="doi">10.1093/jncics/pkab054</article-id>
              <article-id pub-id-type="publisher-id">pkab054</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00010</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title><italic toggle="yes">MAF</italic> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3138-3337</contrib-id>
                  <name>
                    <surname>Paterson</surname>
                    <given-names>Alexander H G</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Department of Oncology, University of Calgary</institution>, Alberta, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4880-7172</contrib-id>
                  <name>
                    <surname>Lucas</surname>
                    <given-names>Peter C</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Department of Pathology, University of Pittsburgh School of Medicine</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>NSABP Foundation and NRG Oncology Biobank</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8948-0650</contrib-id>
                  <name>
                    <surname>Anderson</surname>
                    <given-names>Stewart J</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Department of Biostatistics, Graduate School of Public Health</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mamounas</surname>
                    <given-names>Eleftherios P</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Orlando Health UF Health Cancer Center</institution>, Orlando, FL, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8080-7960</contrib-id>
                  <name>
                    <surname>Brufsky</surname>
                    <given-names>Adam</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>UPMC Hillman Cancer Center, Magee Women’s Hospital University of Pittsburgh</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Baez-Diaz</surname>
                    <given-names>Luis</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>San Juan MBCCOP</institution>, San Juan, PR, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>King</surname>
                    <given-names>Karen M</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Department of Medical Oncology, Cross Cancer Institute</institution>, Edmonton, Alberta, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9258-5522</contrib-id>
                  <name>
                    <surname>Lad</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Stroger Hospital Cook County MU NCORP</institution>, Chicago, IL, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robidoux</surname>
                    <given-names>André</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Centre Hospitalier de l’Université de Montréal</institution>, Montréal, QC, <country country="CA">Canada</country></aff>
                  <xref rid="pkab054-FM1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Finnigan</surname>
                    <given-names>Melanie</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>NSABP Foundation and NRG Oncology Biobank</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1469-3410</contrib-id>
                  <name>
                    <surname>Sampayo</surname>
                    <given-names>Miguel</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <aff><institution>Syntax for Science SL</institution>, Palma de Mallorca, <country country="ES">Spain</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tercero</surname>
                    <given-names>Juan Carlos</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <aff><institution>Inbiomotion SL</institution>, Barcelona, <country country="ES">Spain</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mairet</surname>
                    <given-names>Joël Jean</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <aff><institution>Inbiomotion SL</institution>, Barcelona, <country country="ES">Spain</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3734-1063</contrib-id>
                  <name>
                    <surname>Wolff</surname>
                    <given-names>Antonio C</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Women’s Malignancies Disease Group, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore</institution>, MD, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fehrenbacher</surname>
                    <given-names>Louis</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Kaiser Permanente Medical Center</institution>, Vallejo, CA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wolmark</surname>
                    <given-names>Norman</given-names>
                  </name>
                  <degrees>, MD</degrees>
                  <aff><institution>NSABP Foundation and NRG Oncology</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                  <aff><institution>Department of Biostatistics, Graduate School of Public Health</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6473-2858</contrib-id>
                  <name>
                    <surname>Gomis</surname>
                    <given-names>Roger R</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <aff><institution>Cancer Science, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology</institution>, Barcelona, <country country="ES">Spain</country></aff>
                  <aff><institution>CIBERONC</institution>, <country country="ES">Spain</country></aff>
                  <aff><institution>ICREA, Institució Catalana de Recerca i Estudis Avançats</institution>, Barcelona, <country country="ES">Spain</country></aff>
                  <aff><institution>Universitat de Barcelona</institution>, Barcelona, <country country="ES">Spain</country></aff>
                  <xref rid="pkab054-cor1" ref-type="corresp"/>
                  <!--roger.gomis@irbbarcelona.org-->
                </contrib>
              </contrib-group>
              <author-notes>
                <fn id="pkab054-FM1">
                  <p>André Robidoux Deceased.</p>
                </fn>
                <corresp id="pkab054-cor1">Correspondence to: Roger R. Gomis, PhD, Cancer Science Program, Institute for Research in Biomedicine (IRB Barcelona), PBB52 Parc Scientífic de Barcelona. C/Baldiri i Reixac 10-12, 08028 Barcelona, Spain (e-mail: <email>roger.gomis@irbbarcelona.org</email>).</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-05-28">
                <day>28</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>28</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <volume>5</volume>
              <issue>4</issue>
              <elocation-id>pkab054</elocation-id>
              <history>
                <date date-type="received">
                  <day>04</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="pkab054.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Background</title>
                  <p>The Adjuvant Zoledronic Acid (ZA) study in early breast cancer (AZURE) showed correlation between a nonamplified <italic toggle="yes">MAF</italic> gene in the primary tumor and benefit from adjuvant ZA. Adverse ZA outcomes occurred in MAF-amplified patients. NSABP B-34 is a validation study.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>A retrospective analysis of <italic toggle="yes">MAF</italic> gene status in NSABP B-34 was performed. Eligible patients were randomly assigned to standard adjuvant systemic treatment plus 3 years oral clodronate (1600 mg/daily) or placebo. Tumors were tested for <italic toggle="yes">MAF</italic> gene amplification and analyzed for their relationship to clodronate for disease-free survival (DFS) and overall survival (OS) in <italic toggle="yes">MAF</italic> nonamplified patients. All statistical tests were 2-sided .</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p><italic toggle="yes">MAF</italic> status was assessed in 2533 available primary tumor samples from 3311 patients. Of these, 37 withdrew consent; in 77 samples, no tumor was found; 536 assays did not meet quality standards, leaving 1883 (77.8%) evaluable for <italic toggle="yes">MAF</italic> assay by fluorescence in situ hybridization (947 from placebo and 936 from clodronate arms). At 5 years, in <italic toggle="yes">MAF</italic> nonamplified patients receiving clodronate, DFS improved by 30% (hazard ratio = 0.70, 95% confidence interval = 0.51 to 0.94; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.02). OS improved at 5 years (hazard ratio = 0.59, 95% confidence interval = 0.37 to 0.93; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.02) remaining statistically significant for clodronate throughout study follow-up. Conversely, adjuvant clodronate in women with <italic toggle="yes">MAF</italic>-amplified tumors was not associated with benefit but rather possible harm in some subgroups. Association between MAF status and menopausal status was not seen.</p>
                </sec>
                <sec id="s4">
                  <title>Conclusions</title>
                  <p>Nonamplified <italic toggle="yes">MAF</italic> showed statistically significant benefits (DFS and OS) with oral clodronate, supporting validation of the AZURE study.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>US National Cancer Institute, National Surgical Adjuvant Breast and Bowel Project, Inbiomotion and Bayer Oy (formerly Schering Oy)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>grants from the U10CA180868 (NCI Cancer Trial Network), UG1CA189867 (NCI Community Oncology Research Program), U10CA180822 (NRG Oncology SDMC [Biostats]), U24CA196067-04 (BSB) (Lab)</award-id>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="8"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>Post hoc subset analyses of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-34, AZURE, and other studies showed that benefits with adjuvant bisphosphonates (oral clodronate and IV zoledronic acid [ZA], respectively) for patients with early-stage breast cancer were limited to older or postmenopausal patients (<xref rid="pkab054-B1" ref-type="bibr">1</xref>,<xref rid="pkab054-B2" ref-type="bibr">2</xref>). This observation was supported by an individual patient meta-analysis of adjuvant bisphosphonate (BSP) trials by the Early Breast Cancer Trialists Collaborative Group (EBCTCG) (<xref rid="pkab054-B3" ref-type="bibr">3</xref>). Statistically significant reductions in breast cancer–related mortality were observed in the 11 767 postmenopausal women receiving BSPs (hazard ratio [HR] = 0.82, 95% confidence interval [CI] = 0.73 to 0.93; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.002), leading to European (<xref rid="pkab054-B4" ref-type="bibr">4</xref>) and North American (<xref rid="pkab054-B5" ref-type="bibr">5</xref>) clinical practice guidelines. However, acceptance has been slow. Imprecise definition of the benefiting patient subset is one possible reason.</p>
            <p>Retrospective analysis of the Adjuvant Zoledronic Acid Study in Early Breast Cancer (AZURE) study showed correlation between a nonamplified <italic toggle="yes">MAF</italic> gene in the primary tumor biopsy and statistically significant beneficial effects of adjuvant ZA; adverse effects with ZA were seen in <italic toggle="yes">MAF</italic> -amplified patients (<xref rid="pkab054-B6" ref-type="bibr">6</xref>). These results merited further investigation of <italic toggle="yes">MAF</italic> gene as a potential companion diagnostic in adjuvant BSP’s use in early-stage breast cancer. Validation is required before this biomarker can be routinely used according to recent ESMO bone health in cancer guidelines (<xref rid="pkab054-B7" ref-type="bibr">7</xref>). NSABP B-34 is analyzed here as a validation study (<xref rid="pkab054-B8" ref-type="bibr">8</xref>).</p>
            <p><italic toggle="yes">MAF</italic> amplification (at 16q23) leads to overexpression of MAF (mesenchymal aponeurotic fibrosarcoma gene, an AP-1 family transcription factor) in the primary tumor. This is associated with increased metastasis, especially bone metastasis (<xref rid="pkab054-B9" ref-type="bibr">9</xref>). <italic toggle="yes">MAF</italic> transcriptionally controls genes, such as <italic toggle="yes">CD36</italic> and <italic toggle="yes">PTHrP</italic> (<xref rid="pkab054-B10" ref-type="bibr">10</xref>,<xref rid="pkab054-B11" ref-type="bibr">11</xref>), which regulate metastasis-related cellular processes, including survival, initiation, metabolic rewiring, and particularly, adhesion to bone marrow–derived cells and osteoclast differentiation (<xref rid="pkab054-B12" ref-type="bibr">12</xref>). These observations point to <italic toggle="yes">MAF</italic> having a hierarchical role in metastasis.</p>
            <p><italic toggle="yes">MAF</italic> gene amplification was tested retrospectively in the AZURE trial of adjuvant ZA (<xref rid="pkab054-B1" ref-type="bibr">1</xref>) and showed an association between overall survival (OS) benefit from ZA therapy and lack of an amplified <italic toggle="yes">MAF</italic> gene in the primary tumor (HR<sub>OS</sub> =  0.69, 95% CI = 0.50 to 0.94; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.02). In contrast, patients with <italic toggle="yes">MAF</italic>-amplified tumors who were non-postmenopausal (defined as &gt;5 years postamenorrhea) at treatment start showed poor outcomes with ZA (HR<sub>OS</sub> = 2.28, 95% CI = 1.07 to 4.82; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.03). This difference between <italic toggle="yes">MAF</italic> groups resulted in a net zero effect in the AZURE trial. Using <italic toggle="yes">MAF</italic> as a biomarker showed that <italic toggle="yes">MAF</italic>-negative patients (both postmenopausal and previously unappreciated non-postmenopausal women) were likely to benefit from adjuvant ZA treatment (<xref rid="pkab054-B1" ref-type="bibr">1</xref>,<xref rid="pkab054-B6" ref-type="bibr">6</xref>). This category B analysis of the AZURE trial did not provide a high enough evidence level to propose changes in patient management.</p>
            <p>NSABP B-34 is now analyzed as a validation study using archival tissues from this category B study similarly designed, conducted, and analyzed (<xref rid="pkab054-B13" ref-type="bibr">13</xref>).</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Study Design and Patients</title>
                <p>NSABP B-34 was a randomized, placebo-controlled, double-blind trial of 3323 women with operable breast cancer (stages I-III) at 162 centers in Canada and the United States (NCT00009945). Estrogen (ER) and progesterone receptor (PgR) status was determined (HER2 status testing was not routine in North America at trial start in 2001). Before randomization, patients had a history and physical examination, blood work, and bone scans with radiographs (if indicated). Study procedures and approvals were in accordance with each center’s ethics committee guidelines and the Declaration of Helsinki. Patients gave pre-entry written informed consent.</p>
              </sec>
              <sec>
                <title>Randomization and Masking</title>
                <p>At the NSABP Biostatistical Center (Pittsburgh, PA, USA), eligible patients were randomly assigned (1:1) postsurgery to adjuvant systemic treatment plus 3 years of either oral clodronate (1600 mg daily) or placebo. Participants were masked to group assignment. Stratified randomization was by biased-coin minimization. Patients were stratified (within each center) by age (younger than 50 or 50 years or older), number of positive axillary nodes (0, 1-3, or ≥4), and hormone receptor status. At relapse, study masking and drug was maintained if the patient was bone-metastasis free.</p>
              </sec>
              <sec>
                <title>Procedures</title>
                <p>Patients received postsurgical local and systemic treatments. If indicated, chemotherapy was given concurrently with study drugs; endocrine therapy was administered for 5 years, with treatment choice at investigator’s discretion. Study drugs were discontinued if bone metastasis was detected. Patient follow-up included history and physical examination (with blood work) every 6 months for 5 years and annually thereafter with mammograms (<xref rid="pkab054-B2" ref-type="bibr">2</xref>).</p>
                <p><italic toggle="yes">MAF</italic> gene amplification testing by a central laboratory (Targos Molecular Pathology, Kassel, Germany) was blinded and followed prespecified sample handling and standard operating methodology. Scoring was the same as for the previous AZURE analyses (<xref rid="pkab054-B6" ref-type="bibr">6</xref>) but using full-tissue sections (5-µm thick). Slices were first analyzed for evaluable tumor using hematoxylin and eosin staining. <italic toggle="yes">MAF</italic> amplification was assessed using the analytically validated (<italic toggle="yes">MAF</italic>/D16Z3) fluorescence in situ hybridization (FISH) test MAFTEST (Inbiomotion, Barcelona, Spain).</p>
                <p>Mean <italic toggle="yes">MAF</italic> copy number per nucleus was established from 50 nuclei in tumor regions with highest amplification. Sections were assessed by FISH once, with no option for optimization. A single repetition was allowed if FISH failure was tissue related (eg, section too thick or tissue washed off). Patients were scored as <italic toggle="yes">MAF</italic> positive, indicating <italic toggle="yes">MAF</italic> amplified, with a mean number of 2.5 or more <italic toggle="yes">MAF</italic> copies per nucleus (as defined for the AZURE trial). <italic toggle="yes">MAF</italic> negative means <italic toggle="yes">MAF</italic> nonamplified.</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>The primary objective was to test the predictive association between <italic toggle="yes">MAF</italic> status and adjuvant clodronate outcomes. Endpoint analyses included all patients with follow-up information who were scored in the <italic toggle="yes">MAF</italic> assay. Women withdrawing consent after randomization were excluded. The statistical analysis plan was prespecified and agreed between Division of Biostatistics and Science NRG Oncology (USA), the NSABP, and Syntax For Science (Spain).</p>
                <p>The primary endpoint was disease-free survival (DFS) in <italic toggle="yes">MAF</italic>-negative patients, defined as time from randomization to local, regional, or distant recurrence, contralateral breast cancer, second primary cancer, or death from any cause before breast cancer recurrence. Secondary endpoints were OS (time from randomization to death from any cause), recurrence-free interval (RFI; time from randomization to local, regional, or distant breast cancer recurrence, not including contralateral breast cancer and death from breast cancer), bone metastasis-free interval, and nonbone metastasis-free interval. A hierarchical approach for reduction of alpha consumption was considered for DFS and OS in <italic toggle="yes">MAF</italic>-nonamplified patients.</p>
                <p>Predictive analyses of <italic toggle="yes">MAF</italic> status with treatment allocation used multivariate modeling (Cox proportional hazards model) to adjust for age (2-level factor fitted: 49 years or younger compared with 50 years or older); nodal status (3-level factor: negative, 1-3, ≥4); presence of ER and PgR (2-level factor: both negative, positive for at least 1); histological grade (4-level factor: low, intermediate, high, or missing); and pathological tumor size (4-level factor: ≤2.0 cm, 2.1-4 cm, ≥4.1 cm, unknown). Analyses (including trend analyses) were done at years 5 and 7 and at complete follow-up, given the heterogeneity of treatment regimens between clodronate and ZA (<xref rid="pkab054-B2" ref-type="bibr">2</xref>,<xref rid="pkab054-B14" ref-type="bibr">14</xref>). Menopause and age were included as exploratory endpoints, as no statistically significant heterogeneity of treatment effects within the subgroup of <italic toggle="yes">MAF</italic> negative was observed in AZURE (<xref rid="pkab054-B1" ref-type="bibr">1</xref>,<xref rid="pkab054-B6" ref-type="bibr">6</xref>). The interaction of <italic toggle="yes">MAF</italic> amplification (positive or negative) with treatment allocation has been performed as described before (<xref rid="pkab054-B15" ref-type="bibr">15</xref>).</p>
                <p>Prognostic values of <italic toggle="yes">MAF</italic> status for DFS and OS of patients with early-stage breast cancer in the placebo control group only were investigated as exploratory objectives using survival curves, whereas the endpoints of time to bone metastasis or nonbone metastasis were assessed using cumulative incidence function curves, with death as a competing event. Median survival and incidence rate were estimated using the Kaplan-Meier method. Hazard ratios were obtained using Cox proportional hazards models. The 95% confidence interval values are based on profile-likelihood method, and <italic toggle="yes">P</italic> values are based on likelihood ratio. Hypothesis testing was 2-sided at 5% statistical significance level. All analyses were carried out via SAS, version 9.4 (SAS Institute, Cary, NC).</p>
                <p>Statistical analyses were done at the Syntax For Science (Palma de Mallorca, Spain) and revised and reviewed by the Division of Biostatistics and Science NRG Oncology (Pittsburgh, PA, USA).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <p>We analyzed the <italic toggle="yes">MAF</italic> status of 2533 (76.5%) tumor samples from 3311 patients recruited to the B-34 study between January 22, 2001, and March 31, 2004 (<xref rid="pkab054-F1" ref-type="fig">Figure 1</xref>); 37 patients were ineligible because of consent withdrawal, giving a total of 2496 samples. An invasive tumor was hematoxylin and eosin confirmed in 96.9% (2419 patients), and the <italic toggle="yes">MAF</italic> FISH assay was performed on these samples on adjacent sections and assessed using the stringent quality standards of TARGOS Molecular Pathology. Of these 2419 patients, 1883 (77.8%) were evaluable by <italic toggle="yes">MAF</italic> assay providing FISH results. <italic toggle="yes">MAF</italic>-amplified (<italic toggle="yes">MAF</italic>-positive) tumors were found for 368 (19.5%) of these patients, similar to the 21% reported in the AZURE cohort (<xref rid="pkab054-B6" ref-type="bibr">6</xref>). Overall, <italic toggle="yes">MAF</italic>-evaluable patients (primary analysis set, n = 1883) represented 56.9% of the total B-34 patient cohort, with 947 in the placebo arm and 936 in the clodronate arm.</p>
              <fig position="float" id="pkab054-F1">
                <label>Figure 1.</label>
                <caption>
                  <p>Schematic representation depicting <italic toggle="yes">MAF</italic> test analyses on the NSABP B-34 patient population. The <italic toggle="yes">MAF</italic> status distribution according to patient subgroups is reported. H&amp;E = hematoxilyin and eosin.</p>
                </caption>
                <graphic xlink:href="pkab054f1" position="float"/>
              </fig>
              <p>Median follow-up was 109.5 months (interquartile range = 97.5-120). In this biomarker subset, 406 patients had a DFS event (206 placebo, 200 clodronate), 241 an OS event (133 placebo, 108 clodronate), 236 an RFI event (123 placebo, 113 clodronate), and 88 a bone skeletal event (51 placebo, 37 clodronate). Patient characteristics (<xref rid="pkab054-T1" ref-type="table">Table 1</xref>) and rates of DFS and OS events for the clodronate and placebo arms of the subgroup of <italic toggle="yes">MAF</italic> evaluable patients were similar to the overall B-34 study (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>, available online). Approximately two-thirds of women were 50 years or older on entry, and three-quarters had negative axillary nodes and ER positivity. Both chemotherapy and hormone treatment (mostly tamoxifen) were administered to 45.5% (426 of 936) and 45.6% (432 of 947) of patients receiving clodronate and placebo, respectively (<xref rid="pkab054-T1" ref-type="table">Table 1</xref>). Of the patients, 21.6% (clodronate) and 20.4% (placebo) received chemotherapy alone and 27.4% and 27.5% of the clodronate and placebo received hormone therapy alone.</p>
              <table-wrap position="float" id="pkab054-T1">
                <label>Table 1.</label>
                <caption>
                  <p>Patient clinical characteristics in all B-34 patients according to treatment arm and <italic toggle="yes">MAF</italic> amplification status</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <colgroup span="1">
                    <col valign="top" align="left" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th colspan="2" rowspan="1">Paterson et al. (<xref rid="pkab054-B2" ref-type="bibr">2</xref>)<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref><hr/></th>
                      <th colspan="4" rowspan="1"><italic toggle="yes">MAF</italic> evaluable samples<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref><hr/></th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1">Clinical parameter and subgroups</th>
                      <th rowspan="1" colspan="1">Placebo (n = 1656)<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref></th>
                      <th rowspan="1" colspan="1">Clodronate (n = 1655)<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref></th>
                      <th rowspan="1" colspan="1">Placebo (n = 947)</th>
                      <th rowspan="1" colspan="1">Clodronate (n = 936)</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> negative (n = 1515)</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> positive (n = 368)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="1" colspan="1">Median (IQR) follow-up, mo<xref rid="tblfn4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td rowspan="1" colspan="1">91.5 (83.4-100.0)</td>
                      <td rowspan="1" colspan="1">90.0 (82.3-100.0)</td>
                      <td rowspan="1" colspan="1">111.4 (103.4- 122.1)</td>
                      <td rowspan="1" colspan="1">111.3 (101.7-121.3)</td>
                      <td rowspan="1" colspan="1">111.3 (102.7-121.6)</td>
                      <td rowspan="1" colspan="1">111.8 (101.5-122.2)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Age at entry, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> ≤49 y</td>
                      <td rowspan="1" colspan="1">589 (35.5)</td>
                      <td rowspan="1" colspan="1">594 (35.7)</td>
                      <td rowspan="1" colspan="1">332 (35.1)</td>
                      <td rowspan="1" colspan="1">336 (35.9)</td>
                      <td rowspan="1" colspan="1">526 (34.7)</td>
                      <td rowspan="1" colspan="1">142 (38.6)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> ≥50 y</td>
                      <td rowspan="1" colspan="1">1072 (64.5)</td>
                      <td rowspan="1" colspan="1">1068 (64.3)</td>
                      <td rowspan="1" colspan="1">615 (64.9)</td>
                      <td rowspan="1" colspan="1">600 (64.1)</td>
                      <td rowspan="1" colspan="1">989 (65.3)</td>
                      <td rowspan="1" colspan="1">226 (61.4)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Ethnic origin, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> White</td>
                      <td rowspan="1" colspan="1">1375 (82.8)</td>
                      <td rowspan="1" colspan="1">1381 (83.1)</td>
                      <td rowspan="1" colspan="1">801 (84.6)</td>
                      <td rowspan="1" colspan="1">784 (83.8)</td>
                      <td rowspan="1" colspan="1">1294 (85.4)</td>
                      <td rowspan="1" colspan="1">291 (79.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Hispanic</td>
                      <td rowspan="1" colspan="1">90 (5.4)</td>
                      <td rowspan="1" colspan="1">96 (5.8)</td>
                      <td rowspan="1" colspan="1">41 (4.3)</td>
                      <td rowspan="1" colspan="1">49 (5.2)</td>
                      <td rowspan="1" colspan="1">71 (4.7)</td>
                      <td rowspan="1" colspan="1">19 (5.2)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Black</td>
                      <td rowspan="1" colspan="1">126 (7.6)</td>
                      <td rowspan="1" colspan="1">117 (7.0)</td>
                      <td rowspan="1" colspan="1">63 (6.7)</td>
                      <td rowspan="1" colspan="1">71 (7.6)</td>
                      <td rowspan="1" colspan="1">89 (5.9)</td>
                      <td rowspan="1" colspan="1">45 (12.2)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Pacific Islander</td>
                      <td rowspan="1" colspan="1">9 (&lt;1)</td>
                      <td rowspan="1" colspan="1">4 (&lt;1)</td>
                      <td rowspan="1" colspan="1">7 (0.7)</td>
                      <td rowspan="1" colspan="1">1 (0.1)</td>
                      <td rowspan="1" colspan="1">6 (0.4)</td>
                      <td rowspan="1" colspan="1">2 (0.5)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Asian</td>
                      <td rowspan="1" colspan="1">43 (2.6)</td>
                      <td rowspan="1" colspan="1">48 (2.9)</td>
                      <td rowspan="1" colspan="1">21 (2.2)</td>
                      <td rowspan="1" colspan="1">23 (2.5)</td>
                      <td rowspan="1" colspan="1">37 (2.4)</td>
                      <td rowspan="1" colspan="1">7 (1.9)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> American Indian</td>
                      <td rowspan="1" colspan="1">3 (&lt;1)</td>
                      <td rowspan="1" colspan="1">6 (&lt;1)</td>
                      <td rowspan="1" colspan="1">3 (0.3)</td>
                      <td rowspan="1" colspan="1">3 (0.3)</td>
                      <td rowspan="1" colspan="1">6 (0.4)</td>
                      <td rowspan="1" colspan="1">0 (0.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Other</td>
                      <td rowspan="1" colspan="1">10 (&lt;1)</td>
                      <td rowspan="1" colspan="1">8 (&lt;1)</td>
                      <td rowspan="1" colspan="1">7 (0.7)</td>
                      <td rowspan="1" colspan="1">3 (0.3)</td>
                      <td rowspan="1" colspan="1">6 (0.4)</td>
                      <td rowspan="1" colspan="1">4 (1.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Unknown</td>
                      <td rowspan="1" colspan="1">5 (&lt;1)</td>
                      <td rowspan="1" colspan="1">2 (&lt;1)</td>
                      <td rowspan="1" colspan="1">4 (0.4)</td>
                      <td rowspan="1" colspan="1">2 (0.2)</td>
                      <td rowspan="1" colspan="1">6 (0.4)</td>
                      <td rowspan="1" colspan="1">0 (0.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">No. of positive nodes, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Negative</td>
                      <td rowspan="1" colspan="1">1252 (75.4)</td>
                      <td rowspan="1" colspan="1">1258 (75.7)</td>
                      <td rowspan="1" colspan="1">737 (77.8)</td>
                      <td rowspan="1" colspan="1">694 (74.1)</td>
                      <td rowspan="1" colspan="1">1159 (76.5)</td>
                      <td rowspan="1" colspan="1">272 (73.9)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> 1-3</td>
                      <td rowspan="1" colspan="1">295 (17.8)</td>
                      <td rowspan="1" colspan="1">296 (17.8)</td>
                      <td rowspan="1" colspan="1">147 (15.5)</td>
                      <td rowspan="1" colspan="1">176 (18.8)</td>
                      <td rowspan="1" colspan="1">259 (17.1)</td>
                      <td rowspan="1" colspan="1">64 (17.4)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> 4 or more</td>
                      <td rowspan="1" colspan="1">114 (6.9)</td>
                      <td rowspan="1" colspan="1">108 (6.5)</td>
                      <td rowspan="1" colspan="1">63 (6.7)</td>
                      <td rowspan="1" colspan="1">66 (7.1)</td>
                      <td rowspan="1" colspan="1">97 (6.4)</td>
                      <td rowspan="1" colspan="1">32 (8.7)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Hormone receptor status, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Both negative</td>
                      <td rowspan="1" colspan="1">368 (22.2)</td>
                      <td rowspan="1" colspan="1">368 (22.1)</td>
                      <td rowspan="1" colspan="1">202 (21.3)</td>
                      <td rowspan="1" colspan="1">223 (23.8)</td>
                      <td rowspan="1" colspan="1">247 (16.3)</td>
                      <td rowspan="1" colspan="1">178 (48.4)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Either or both positive</td>
                      <td rowspan="1" colspan="1">1293 (77.8)</td>
                      <td rowspan="1" colspan="1">1294 (77.9)</td>
                      <td rowspan="1" colspan="1">745 (78.7)</td>
                      <td rowspan="1" colspan="1">713 (76.2)</td>
                      <td rowspan="1" colspan="1">1268 (83.7)</td>
                      <td rowspan="1" colspan="1">190 (51.6)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Adjuvant therapy, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Chemotherapy alone</td>
                      <td rowspan="1" colspan="1">344 (20.8)</td>
                      <td rowspan="1" colspan="1">342 (20.7)</td>
                      <td rowspan="1" colspan="1">193 (20.4)</td>
                      <td rowspan="1" colspan="1">203 (21.6)</td>
                      <td rowspan="1" colspan="1">238 (15.7)</td>
                      <td rowspan="1" colspan="1">158 (42.9)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Hormonal therapy alone</td>
                      <td rowspan="1" colspan="1">518 (31.3)</td>
                      <td rowspan="1" colspan="1">512 (30.9)</td>
                      <td rowspan="1" colspan="1">260 (27.5)</td>
                      <td rowspan="1" colspan="1">257 (27.4)</td>
                      <td rowspan="1" colspan="1">470 (31.0)</td>
                      <td rowspan="1" colspan="1">47 (12.8)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Both</td>
                      <td rowspan="1" colspan="1">720 (43.5)</td>
                      <td rowspan="1" colspan="1">728 (44.0)</td>
                      <td rowspan="1" colspan="1">432 (45.6)</td>
                      <td rowspan="1" colspan="1">426 (45.5)</td>
                      <td rowspan="1" colspan="1">713 (47.1)</td>
                      <td rowspan="1" colspan="1">145 (39.4)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> None</td>
                      <td rowspan="1" colspan="1">53 (3.2)</td>
                      <td rowspan="1" colspan="1">51 (3.1)</td>
                      <td rowspan="1" colspan="1">28 (3.0)</td>
                      <td rowspan="1" colspan="1">26 (2.8)</td>
                      <td rowspan="1" colspan="1">39 (2.6)</td>
                      <td rowspan="1" colspan="1">15 (4.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Unknown</td>
                      <td rowspan="1" colspan="1">26 (1.6)</td>
                      <td rowspan="1" colspan="1">29 (1.8)</td>
                      <td rowspan="1" colspan="1">8 (0.8)</td>
                      <td rowspan="1" colspan="1">9 (1.0)</td>
                      <td rowspan="1" colspan="1">13 (0.9)</td>
                      <td rowspan="1" colspan="1">4 (1.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Pathological tumor size, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> ≤2.0 cm</td>
                      <td rowspan="1" colspan="1">1119 (67.4)</td>
                      <td rowspan="1" colspan="1">1127 (67.8)</td>
                      <td rowspan="1" colspan="1">640 (67.6)</td>
                      <td rowspan="1" colspan="1">617 (65.9)</td>
                      <td rowspan="1" colspan="1">1045 (69.0)</td>
                      <td rowspan="1" colspan="1">212 (57.6)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> 2.1-4.0 cm</td>
                      <td rowspan="1" colspan="1">456 (27.5)</td>
                      <td rowspan="1" colspan="1">466 (28.0)</td>
                      <td rowspan="1" colspan="1">261 (27.6)</td>
                      <td rowspan="1" colspan="1">282 (30.1)</td>
                      <td rowspan="1" colspan="1">410 (27.1)</td>
                      <td rowspan="1" colspan="1">133 (36.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> ≥4.1 cm</td>
                      <td rowspan="1" colspan="1">81 (4.9)</td>
                      <td rowspan="1" colspan="1">64 (3.9)</td>
                      <td rowspan="1" colspan="1">46 (4.9)</td>
                      <td rowspan="1" colspan="1">37 (4.0)</td>
                      <td rowspan="1" colspan="1">60 (4.0)</td>
                      <td rowspan="1" colspan="1">23 (6.3)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Unknown</td>
                      <td rowspan="1" colspan="1">5 (&lt;1)</td>
                      <td rowspan="1" colspan="1">5 (&lt;1)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Histological grade, No. (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Low</td>
                      <td rowspan="1" colspan="1">374 (22.5)</td>
                      <td rowspan="1" colspan="1">377 (22.7)</td>
                      <td rowspan="1" colspan="1">198 (20.9)</td>
                      <td rowspan="1" colspan="1">196 (20.9)</td>
                      <td rowspan="1" colspan="1">370 (24.4)</td>
                      <td rowspan="1" colspan="1">24 (6.5)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Intermediate</td>
                      <td rowspan="1" colspan="1">665 (40.0)</td>
                      <td rowspan="1" colspan="1">667 (40.1)</td>
                      <td rowspan="1" colspan="1">386 (40.8)</td>
                      <td rowspan="1" colspan="1">378 (40.4)</td>
                      <td rowspan="1" colspan="1">661 (43.6)</td>
                      <td rowspan="1" colspan="1">103 (28.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> High</td>
                      <td rowspan="1" colspan="1">589 (35.5)</td>
                      <td rowspan="1" colspan="1">575 (34.6)</td>
                      <td rowspan="1" colspan="1">351 (37.1)</td>
                      <td rowspan="1" colspan="1">344 (36.8)</td>
                      <td rowspan="1" colspan="1">456 (30.1)</td>
                      <td rowspan="1" colspan="1">239 (64.9)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Unknown</td>
                      <td rowspan="1" colspan="1">28 (1.7)</td>
                      <td rowspan="1" colspan="1">36 (2.2)</td>
                      <td rowspan="1" colspan="1">12 (1.3)</td>
                      <td rowspan="1" colspan="1">18 (1.9)</td>
                      <td rowspan="1" colspan="1">28 (1.8)</td>
                      <td rowspan="1" colspan="1">2 (0.5)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="tblfn1">
                    <label>a</label>
                    <p>3323 patients were randomly assigned: 1661 to placebo and 1662 to clodronate. There were 3311 patients with follow-up data. IQR = interquartile range.</p>
                  </fn>
                  <fn id="tblfn2">
                    <label>b</label>
                    <p>There were 2533 tumor samples for <italic toggle="yes">MAF</italic> test and 1883 <italic toggle="yes">MAF</italic> evaluable patients in the primary set.</p>
                  </fn>
                  <fn id="tblfn3">
                    <label>c</label>
                    <p>Patients with follow-up data.</p>
                  </fn>
                  <fn id="tblfn4">
                    <label>d</label>
                    <p>Based on 1648 patients reported to be alive at last follow-up.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The frequency of <italic toggle="yes">MAF</italic>-positive status was unaffected by age or axillary lymph node status but was more common with poor histological grade, ER negativity, and larger tumors (<xref rid="pkab054-T1" ref-type="table">Table 1</xref>). Consequently, women with <italic toggle="yes">MAF</italic>-positive tumors were more likely to have received chemotherapy and less likely to have had endocrine treatments than the group as a whole. Given the heterogeneity of the prognostic factors in the baseline demographics, predictive results are reported using multivariate Cox modeling, adjusted by age, nodal status, ER and PgR status, histological grade, and pathological tumor size.</p>
              <p>For patients with <italic toggle="yes">MAF</italic>-nonamplified tumors (<italic toggle="yes">MAF</italic> negative), clodronate treatment showed improved DFS at 5 years compared with placebo (HR = 0.70, 95% CI = 0.51 to 0.94; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.02) (<xref rid="pkab054-F2" ref-type="fig">Figure 2, A</xref>), although this association is no longer statistically significant with longer follow-up times (<xref rid="pkab054-T2" ref-type="table">Table 2;</xref><xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1, A</xref>, available online). At 5 years, patients with <italic toggle="yes">MAF</italic>-negative tumors had a 41.0% reduction in hazard for death (HR = 0.59, 95% CI = 0.37 to 0.93; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.02) (<xref rid="pkab054-F2" ref-type="fig">Figure 2, B</xref>). Fewer patients with <italic toggle="yes">MAF</italic>-negative tumors treated with clodronate died (n = 30; 4.0%) compared with the placebo group (n = 47; 6.1%). Next, we tested <italic toggle="yes">MAF</italic> and treatment interaction even though the <italic toggle="yes">MAF</italic>-negative subgroup and its <italic toggle="yes">MAF</italic>-positive complement are different in size (4 to 1) and the heterogeneity test loses power. Yet, under these unfavorable circumstances and although the study was not powered to detect treatment by <italic toggle="yes">MAF</italic> status interactions, a clear trend is detected comparing the OS outcomes of <italic toggle="yes">MAF</italic> (+) vs (–) patients with a <italic toggle="yes">P</italic><sub>interaction</sub> of .06. The benefit in OS in <italic toggle="yes">MAF</italic>-negative patients was statistically significant at all timepoints (<xref rid="pkab054-T2" ref-type="table">Table 2;</xref><xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1, B</xref>, available online); these benefits were not observed for <italic toggle="yes">MAF</italic>-positive patients (<xref rid="pkab054-T2" ref-type="table">Table 2</xref>) or for the overall cohort (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>, available online) and did not associate statistically significantly with age or menopausal status (younger than 50 years: HR = 0.80, 95% CI = 0.43 to 1.49; and 50 years or older: HR = 0.72, 95% CI = 0.51 to 1.02) (<xref rid="pkab054-T3" ref-type="table">Table 3</xref>). The clodronate group’s absolute death risk reduction at complete follow-up in <italic toggle="yes">MAF</italic>-negative patients was 2.8% (from 12.4% for placebo to 9.6% for clodronate, a 22.6% reduction in death).</p>
              <fig position="float" id="pkab054-F2">
                <label>Figure 2.</label>
                <caption>
                  <p>Disease-free survival (<bold>A</bold>) and percentage who died (<bold>B</bold>) by treatment group in <italic toggle="yes">MAF</italic>-nonamplified patients at 5-year follow-up from Cox multivariable model adjusted for differences in age, nodal status, presence of estrogen and progesterone, histological grade, and pathological tumor size. All statistical tests are 2-sided. CI = confidence interval; CLO = Clodronate; HR = hazard ratio .</p>
                </caption>
                <graphic xlink:href="pkab054f2" position="float"/>
              </fig>
              <table-wrap position="float" id="pkab054-T2">
                <label>Table 2.</label>
                <caption>
                  <p>Outcomes of the trial endpoints according to patients subgroups and follow-up time<xref rid="tblfn5" ref-type="table-fn"><sup>a</sup></xref></p>
                </caption>
                <table frame="hsides" rules="groups">
                  <colgroup span="1">
                    <col valign="top" align="left" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th rowspan="2" colspan="1">Endpoint</th>
                      <th colspan="2" rowspan="1">5 years<hr/></th>
                      <th colspan="2" rowspan="1">7 years<hr/></th>
                      <th colspan="2" rowspan="1">Median follow of 109 months<hr/></th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> negative (n = 1515)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> OS</td>
                      <td rowspan="1" colspan="1">0.59 (0.37 to 0.93)</td>
                      <td rowspan="1" colspan="1">.02</td>
                      <td rowspan="1" colspan="1">0.69 (0.48 to 1.00)</td>
                      <td rowspan="1" colspan="1">.047</td>
                      <td rowspan="1" colspan="1">0.74 (0.54 to 1.00)</td>
                      <td rowspan="1" colspan="1">.046</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> DFS</td>
                      <td rowspan="1" colspan="1">0.70 (0.51 to 0.94)</td>
                      <td rowspan="1" colspan="1">.02</td>
                      <td rowspan="1" colspan="1">0.83 (0.64 to 1.07)</td>
                      <td rowspan="1" colspan="1">.15</td>
                      <td rowspan="1" colspan="1">0.93 (0.74 to 1.16)</td>
                      <td rowspan="1" colspan="1">.52</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> RFI</td>
                      <td rowspan="1" colspan="1">0.67 (0.45 to 0.98)</td>
                      <td rowspan="1" colspan="1">.04</td>
                      <td rowspan="1" colspan="1">0.82 (0.58 to 1.14)</td>
                      <td rowspan="1" colspan="1">.24</td>
                      <td rowspan="1" colspan="1">0.91 (0.67 to 1.23)</td>
                      <td rowspan="1" colspan="1">.53</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Bone metastases</td>
                      <td rowspan="1" colspan="1">0.89 (0.47 to 1.68)</td>
                      <td rowspan="1" colspan="1">.71</td>
                      <td rowspan="1" colspan="1">0.79 (0.46 to 1.37)</td>
                      <td rowspan="1" colspan="1">.40</td>
                      <td rowspan="1" colspan="1">0.82 (0.50 to 1.34)</td>
                      <td rowspan="1" colspan="1">.43</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Nonbone metastases</td>
                      <td rowspan="1" colspan="1">0.70 (0.42 to 1.17)</td>
                      <td rowspan="1" colspan="1">.17</td>
                      <td rowspan="1" colspan="1">0.82 (0.52 to 1.28)</td>
                      <td rowspan="1" colspan="1">.38</td>
                      <td rowspan="1" colspan="1">0.73 (0.48 to 1.10)</td>
                      <td rowspan="1" colspan="1">.13</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> positive (n = 368)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> OS</td>
                      <td rowspan="1" colspan="1">1.39 (0.71 to 2.70)</td>
                      <td rowspan="1" colspan="1">.34</td>
                      <td rowspan="1" colspan="1">1.26 (0.70 to 2.28)</td>
                      <td rowspan="1" colspan="1">.44</td>
                      <td rowspan="1" colspan="1">1.01 (0.62 to 1.67)</td>
                      <td rowspan="1" colspan="1">.96</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> DFS</td>
                      <td rowspan="1" colspan="1">1.00 (0.62 to 1.61)</td>
                      <td rowspan="1" colspan="1">1.00</td>
                      <td rowspan="1" colspan="1">1.05 (0.67 to 1.64)</td>
                      <td rowspan="1" colspan="1">.83</td>
                      <td rowspan="1" colspan="1">1.06 (0.70 to 1.59)</td>
                      <td rowspan="1" colspan="1">.79</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> RFI</td>
                      <td rowspan="1" colspan="1">0.83 (0.46 to 1.49)</td>
                      <td rowspan="1" colspan="1">.53</td>
                      <td rowspan="1" colspan="1">0.78 (0.45 to 1.35)</td>
                      <td rowspan="1" colspan="1">.37</td>
                      <td rowspan="1" colspan="1">0.81 (0.49 to 1.35)</td>
                      <td rowspan="1" colspan="1">.42</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Bone metastases</td>
                      <td rowspan="1" colspan="1">0.44 (0.14 to 1.39)</td>
                      <td rowspan="1" colspan="1">.16</td>
                      <td rowspan="1" colspan="1">0.33 (0.11 to 0.98)</td>
                      <td rowspan="1" colspan="1">.046</td>
                      <td rowspan="1" colspan="1">0.40 (0.15 to 1.06)</td>
                      <td rowspan="1" colspan="1">.06</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Nonbone metastases</td>
                      <td rowspan="1" colspan="1">0.70 (0.31 to 1.55)</td>
                      <td rowspan="1" colspan="1">.38</td>
                      <td rowspan="1" colspan="1">0.60 (0.28 to 1.26)</td>
                      <td rowspan="1" colspan="1">.17</td>
                      <td rowspan="1" colspan="1">0.62 (0.30 to 1.27)</td>
                      <td rowspan="1" colspan="1">.19</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="tblfn5">
                    <label>a</label>
                    <p>All statistical tests were 2-sided. CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; OS = overall survival; RFI = recurrence-free interval.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="pkab054-T3">
                <label>Table 3.</label>
                <caption>
                  <p>Outcomes of the trial endpoints according to patients subgroups<xref rid="tblfn6" ref-type="table-fn"><sup>a</sup></xref></p>
                </caption>
                <table frame="hsides" rules="groups">
                  <colgroup span="1">
                    <col valign="top" align="left" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th rowspan="2" colspan="1">Endpoint</th>
                      <th colspan="2" rowspan="1">≤49 y<hr/></th>
                      <th colspan="2" rowspan="1">≥50 y<hr/></th>
                      <th colspan="2" rowspan="1">Premenopausal<hr/></th>
                      <th colspan="2" rowspan="1">Postmenopausal<hr/></th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> negative</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> positive</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> negative</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> positive</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> negative</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> positive</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> negative</th>
                      <th rowspan="1" colspan="1"><italic toggle="yes">MAF</italic> positive</th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th rowspan="1" colspan="1">(n = 526)</th>
                      <th rowspan="1" colspan="1">(n = 142)</th>
                      <th rowspan="1" colspan="1">(n = 989)</th>
                      <th rowspan="1" colspan="1">(n = 226)</th>
                      <th rowspan="1" colspan="1">(n = 466)</th>
                      <th rowspan="1" colspan="1">(n = 111)</th>
                      <th rowspan="1" colspan="1">(n = 535)</th>
                      <th rowspan="1" colspan="1">(n = 138)</th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                      <th rowspan="1" colspan="1">HR (95% CI)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="1" colspan="1">DFS</td>
                      <td rowspan="1" colspan="1">0.98 (0.63 to 1.51)</td>
                      <td rowspan="1" colspan="1">0.73 (0.36 to 1.43)</td>
                      <td rowspan="1" colspan="1">0.91 (0.70 to 1.18)</td>
                      <td rowspan="1" colspan="1">1.23 (0.75 to 2.04)</td>
                      <td rowspan="1" colspan="1">1.14 (0.68 to 1.90)</td>
                      <td rowspan="1" colspan="1">0.88 (0.43 to 1.79)</td>
                      <td rowspan="1" colspan="1">0.83 (0.59 to 1.16)</td>
                      <td rowspan="1" colspan="1">1.42 (0.75 to 2.79)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">OS</td>
                      <td rowspan="1" colspan="1">0.80 (0.43 to 1.49)</td>
                      <td rowspan="1" colspan="1">0.91 (0.37 to 2.17)</td>
                      <td rowspan="1" colspan="1">0.72 (0.51 to 1.02)</td>
                      <td rowspan="1" colspan="1">0.96 (0.54 to 1.71)</td>
                      <td rowspan="1" colspan="1">0.88 (0.41 to 1.86)</td>
                      <td rowspan="1" colspan="1">1.02 (0.38 to 2.68)</td>
                      <td rowspan="1" colspan="1">0.72 (0.46 to 1.12)</td>
                      <td rowspan="1" colspan="1">1.20 (0.58 to 2.53)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">RFI</td>
                      <td rowspan="1" colspan="1">1.06 (0.64 to 1.76)</td>
                      <td rowspan="1" colspan="1">0.60 (0.26 to 1.31)</td>
                      <td rowspan="1" colspan="1">0.85 (0.58 to 1.23)</td>
                      <td rowspan="1" colspan="1">0.96 (0.50 to 1.84)</td>
                      <td rowspan="1" colspan="1">1.25 (0.68 to 2.33)</td>
                      <td rowspan="1" colspan="1">0.85 (0.38 to 1.84)</td>
                      <td rowspan="1" colspan="1">0.74 (0.45 to 1.22)</td>
                      <td rowspan="1" colspan="1">1.05 (0.44 to 2.52)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Bone metastases</td>
                      <td rowspan="1" colspan="1">1.32 (0.60 to 3.03)</td>
                      <td rowspan="1" colspan="1">0.34 (0.05 to 1.37)</td>
                      <td rowspan="1" colspan="1">0.61 (0.32 to 1.15)</td>
                      <td rowspan="1" colspan="1">0.42 (0.11 to 1.35)</td>
                      <td rowspan="1" colspan="1">1.78 (0.62 to 5.78)</td>
                      <td rowspan="1" colspan="1">0.49 (0.11 to 1.78)</td>
                      <td rowspan="1" colspan="1">0.59 (0.26 to 1.29)</td>
                      <td rowspan="1" colspan="1">0.45 (0.06 to 2.31)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Nonbone metastases</td>
                      <td rowspan="1" colspan="1">0.77 (0.38 to 1.51)</td>
                      <td rowspan="1" colspan="1">0.64 (0.17 to 2.06)</td>
                      <td rowspan="1" colspan="1">0.74 (0.44 to 1.23)</td>
                      <td rowspan="1" colspan="1">0.57 (0.23 to 1.32)</td>
                      <td rowspan="1" colspan="1">0.76 (0.33 to 1.72)</td>
                      <td rowspan="1" colspan="1">0.70 (0.18 to 2.34)</td>
                      <td rowspan="1" colspan="1">0.69 (0.35 to 1.32)</td>
                      <td rowspan="1" colspan="1">0.64 (0.21 to 1.84)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="tblfn6">
                    <label>a</label>
                    <p>CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; OS = overall survival; RFI = recurrence-free interval.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>RFI showed an association between treatment and <italic toggle="yes">MAF</italic> status at 5-year follow-up similar to DFS. Statistically significantly fewer patients with <italic toggle="yes">MAF</italic>-negative tumors in the clodronate patients had breast cancer–related events (n = 45; 6%) than those in the placebo group (n = 60, 7.8%; HR = 0.67, 95% CI = 0.45 to 0.98; <italic toggle="yes">P = </italic>.04) (<xref rid="pkab054-T2" ref-type="table">Table 2</xref>). For <italic toggle="yes">MAF</italic>-positive patients, no clodronate treatment effect was observed for DFS, RFI, and OS at different follow-up times (<xref rid="pkab054-T2" ref-type="table">Table 2</xref>), with a nonsignificant association to poorer OS—more evident in times closer to the treatment period. In exploratory analyses, we tested the impact of clodronate on bone and nonbone metastasis in <italic toggle="yes">MAF</italic>-positive and <italic toggle="yes">MAF</italic>-negative subgroups, but a statistically significant association was absent likely because of low event numbers.</p>
              <p>To determine that <italic toggle="yes">MAF</italic> negativity or positivity associates with DFS and OS (ie, is prognostic), we assessed its influence on outcome in the placebo control group. Disease progression was observed for 48 of 181 (26.5%) patients with <italic toggle="yes">MAF</italic>-positive tumors and for 158 of 766 (20.6%) patients with <italic toggle="yes">MAF</italic>-negative tumors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>, available online) confirming that <italic toggle="yes">MAF</italic> status was prognostic (HR = 1.39, 95% CI = 1.01 to 1.92; <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.045) for DFS (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2, A</xref>, available online). <italic toggle="yes">MAF</italic> status was also prognostic for OS, RFI, and metastasis (bone and nonbone) (<xref rid="pkab054-T4" ref-type="table">Table 4</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2, B</xref>, available online).</p>
              <table-wrap position="float" id="pkab054-T4">
                <label>Table 4.</label>
                <caption>
                  <p>Prognostic of outcome in placebo control arm patients (n = 947)<xref rid="tblfn7" ref-type="table-fn"><sup>a</sup></xref></p>
                </caption>
                <table frame="hsides" rules="groups">
                  <colgroup span="1">
                    <col valign="top" align="left" span="1"/>
                    <col valign="top" align="char" char="." span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="char" char="." span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th rowspan="1" colspan="1">Endpoint and <italic toggle="yes">MAF</italic> group</th>
                      <th rowspan="1" colspan="1">No.<xref rid="tblfn8" ref-type="table-fn"><sup>b</sup></xref></th>
                      <th rowspan="1" colspan="1">Univariable HR (95% CI)</th>
                      <th rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                        <xref rid="tblfn9" ref-type="table-fn">
                          <sup>c</sup>
                        </xref>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="1" colspan="1">DFS</td>
                      <td rowspan="1" colspan="1">947</td>
                      <td rowspan="1" colspan="1">1.39 (1.01 to 1.92)</td>
                      <td rowspan="1" colspan="1">.045</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">OS</td>
                      <td rowspan="1" colspan="1">947</td>
                      <td rowspan="1" colspan="1">1.59 (1.59 to 2.33)</td>
                      <td rowspan="1" colspan="1">.02</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">RFI</td>
                      <td rowspan="1" colspan="1">947</td>
                      <td rowspan="1" colspan="1">1.88 (1.27 to 2.77)</td>
                      <td rowspan="1" colspan="1">.02</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Bone metastases</td>
                      <td rowspan="1" colspan="1">947</td>
                      <td rowspan="1" colspan="1">2.03 (1.13 to 3.68)</td>
                      <td rowspan="1" colspan="1">.02</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Nonbone metastases</td>
                      <td rowspan="1" colspan="1">947</td>
                      <td rowspan="1" colspan="1">1.81 (1.09 to 3.00)</td>
                      <td rowspan="1" colspan="1">.02</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="tblfn7">
                    <label>a</label>
                    <p>Median follow up. CI = confidence interval; DFS = disease-free survival; HR = hazard ratio (MAF+ve/-ve); OS = overall survival; RFI = recurrence-free interval.</p>
                  </fn>
                  <fn id="tblfn8">
                    <label>b</label>
                    <p>766 <italic toggle="yes">MAF</italic>-negative patients and 181 <italic toggle="yes">MAF</italic>-positive patients.</p>
                  </fn>
                  <fn id="tblfn9">
                    <label>c</label>
                    <p>All statistical tests are 2-sided.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Bisphosphonates are bone-targeting drugs binding to sites of bone resorption; after internalization by osteoclasts, bisphosphonates inhibit their function. Although rapidly cleared from the circulation, they have a long bone half-life and are effective in conditions with excessive bone resorption, including osteoporosis. They are useful in managing bone metastases in breast cancer–reducing skeletal–related events and improving life quality (<xref rid="pkab054-B7" ref-type="bibr">7</xref>,<xref rid="pkab054-B16" ref-type="bibr">16</xref>).</p>
              <p>The bisphosphonates clodronate and ZA differ in how they inhibit osteoclast activity and induce apoptosis: amino-bisphosphonates (such as ZA) inhibit farnesyl pyrophosphate synthase (an enzyme crucial to cell growth and division), whereas nonamino-bisphosphonates (eg, clodronate) form cytotoxic metabolites (<xref rid="pkab054-B17" ref-type="bibr">17</xref>). The SWOG S0307 (<xref rid="pkab054-B18" ref-type="bibr">18</xref>) study confirmed that clodronate and ZA give equivalent outcomes in adjuvant breast cancer.</p>
              <p>In an early open-label study, clodronate reduced bone metastasis frequency and increased survival in women with evidence of disseminated bone marrow cancer cells (<xref rid="pkab054-B19" ref-type="bibr">19</xref>), but 2 subsequent trials gave conflicting results. A large placebo-controlled study by Powles et al. (<xref rid="pkab054-B20" ref-type="bibr">20</xref>) showed statistically significant benefit for bone metastasis-free survival and overall survival in all women with breast cancer receiving adjuvant oral clodronate. However, a smaller open-label study (mainly in premenopausal women) suggested possible potential harm from clodronate (<xref rid="pkab054-B21" ref-type="bibr">21</xref>). In 2012, Gnant et al. (<xref rid="pkab054-B22" ref-type="bibr">22</xref>) reported a survival benefit with ZA for women receiving ovarian suppression plus tamoxifen or anastrozole for ER-positive cancer.</p>
              <p>Looking for confirmatory studies, 2 larger trials over longer periods of adjuvant bisphosphonate treatment (clodronate for 3 years and ZA for 5 years) commenced (<xref rid="pkab054-B2" ref-type="bibr">2</xref>,<xref rid="pkab054-B14" ref-type="bibr">14</xref>). Neither trial met its primary endpoint (DFS) although retrospective subset analyses in B-34 showed that patients older than 50 years or who were postmenopausal more than 5 years in AZURE had statistically significant treatment benefits with adjuvant clodronate and ZA. This suggested that adjuvant bisphosphonates might be efficacious for postmenopausal patients. Subsequently, an individual patient meta-analysis by the EBCTCG (<xref rid="pkab054-B3" ref-type="bibr">3</xref>) showed a clear reduction in breast cancer mortality in postmenopausal patients (HR<sub>OS</sub> = 0.82, 95% CI = 0.73 to 0.93; 2-sided <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>.002). This influential meta-analysis led to guidelines recommending adjuvant IV ZA or oral clodronate for postmenopausal women to reduce relapse in bone and overall survival (<xref rid="pkab054-B4" ref-type="bibr">4</xref>,<xref rid="pkab054-B5" ref-type="bibr">5</xref>). Because of low event numbers for bone metastases (51 placebo vs 37 clodronate), we are unable to comment specifically on bone relapse. However, the lack of a clear mechanistic explanation why bisphosphonates benefit only a subgroup of often hard-to-define patients is an unmet medical need defined in ASCO (<xref rid="pkab054-B5" ref-type="bibr">5</xref>) and ESMO bone health in cancer guidelines (<xref rid="pkab054-B7" ref-type="bibr">7</xref>). The latter states that the <italic toggle="yes">MAF</italic> biomarker may predict benefit (and harm) from bone microenvironment manipulation. Validation in an independent trial is required before routine use (<xref rid="pkab054-B7" ref-type="bibr">7</xref>). Clodronate and ZA both act on osseous stroma and not on tumor cells and are considered clinically equi-efficacious. Difference in pharmacological potency may account for the harm seen in <italic toggle="yes">MAF</italic>-positive patients in AZURE, though this is conjecture at this point.</p>
              <p>The hypothesis that a negative <italic toggle="yes">MAF</italic> gene amplification result (<italic toggle="yes">MAF</italic> negative) measured by FISH might predict benefit from adjuvant clodronate treatment came from the AZURE study of ZA (<xref rid="pkab054-B1" ref-type="bibr">1</xref>,<xref rid="pkab054-B6" ref-type="bibr">6</xref>). In the B-34 study, we tested tissue samples, paraffin-fixed and archived for 15-19 years, using current standard practices. Of the samples, 3% had insufficient tumor tissue, and 25% were unevaluable by the <italic toggle="yes">MAF</italic> assay because of long storage times, explaining the attrition of patients for MAFTEST testing; however, this still met criteria for the preplanned statistical analyses. Of note, in samples stored less than 1 year, the rate of FISH failure was lower (2%-5%) and mostly attributable to the lack of relevant tumor tissue for analysis. The available two-thirds of the total accrued patients’ specimens were representative of the original cohort. Adjuvant clodronate improved disease outcome (DFS and OS) for the 80.3% of patients with <italic toggle="yes">MAF</italic>-negative tumors independent of age or menopause at study entry. Conversely, the use of adjuvant clodronate in women with <italic toggle="yes">MAF</italic>-positive tumors was not associated with any treatment benefit, supporting the previously published data on the <italic toggle="yes">MAF</italic> biomarker in AZURE (<xref rid="pkab054-B1" ref-type="bibr">1</xref>,<xref rid="pkab054-B6" ref-type="bibr">6</xref>).</p>
              <p>For a biomarker, interpretable evaluation using archived tissues requires the assay to reflect what would happen in a clinical setting. The current analysis provides level-1 evidence by presenting a category B confirmation of a previous category B hypothesis-generating study (<xref rid="pkab054-B13" ref-type="bibr">13</xref>). In AZURE, <italic toggle="yes">MAF</italic>-negative patients receiving ZA had a statistically significantly improved invasive DFS (IDFS ) and survival, whereas <italic toggle="yes">MAF</italic>-positive patients had a reduced IDFS and survival. In NSABP B-34, we confirm that <italic toggle="yes">MAF</italic>-negative patients have a statistically significant improvement in DFS and OS, whereas <italic toggle="yes">MAF</italic>-positive patients had no benefit with adjuvant bisphosphonates. The absolute death risk reductions at 5 years were 5.8% and 2.8%, respectively (a 25.3% reduction in DFS and 35.7% reduction in death events on clodronate treatment). These are in line with those for IDFS for pertuzumab in adjuvant treatment of HER2-positive breast cancer patients (<xref rid="pkab054-B23" ref-type="bibr">23</xref>) and of higher magnitude than those reported by NICE (<xref rid="pkab054-B24" ref-type="bibr">24</xref>) to approve the use of bisphosphonates in postmenopausal patients in the United Kingdom on the basis of the EBCTCG meta-analysis (<xref rid="pkab054-B3" ref-type="bibr">3</xref>). The confirmation in a study with a high proportion of stage I patients as opposed to stage II and III disease in AZURE has implications for routine clinical practice. At present, the guidelines suggest treatment is limited to patients at intermediate to high risk of relapse, perhaps reflecting some uncertainty over the best way to apply the EBCTCG findings to routine clinical practice. Clinical guidelines in Europe (<xref rid="pkab054-B4" ref-type="bibr">4</xref>) and North America (<xref rid="pkab054-B5" ref-type="bibr">5</xref>) might now be supported by an objective diagnostic test.</p>
              <p><italic toggle="yes">MAF</italic> biomarker selection should allow (with more precise identification of a benefiting subgroup) higher treatment adoption rates, including younger premenopausal patients currently excluded in guidelines. Our study shows (<xref rid="pkab054-T1" ref-type="table">Table 1</xref>) 670 patients who were <italic toggle="yes">MAF</italic> evaluable were aged 49 years or younger (and likely clinically classified as premenopausal) with 526 being <italic toggle="yes">MAF</italic> negative (78.5%) who might have benefited from bisphosphonates. Data from these 2 studies suggest that beneficial effects of bisphosphonates for breast cancer are associated with the absence of an amplified <italic toggle="yes">MAF</italic> gene in the primary tumor (<italic toggle="yes">MAF</italic> negative); bisphosphonates do not improve outcome (and may harm) women with <italic toggle="yes">MAF</italic>-amplified tumors (<italic toggle="yes">MAF</italic> positive).</p>
              <p>According to <italic toggle="yes">MAF</italic>, as opposed to menopause (as currently recommended by guidelines), identifying <italic toggle="yes">MAF</italic>-negative patients could give a larger patient population the opportunity to benefit from adjuvant bisphosphonates while avoiding potential harm (or no benefit) than solely using menopausal status as a selection criterion (<xref rid="pkab054-F3" ref-type="fig">Figure 3</xref>).</p>
              <fig position="float" id="pkab054-F3">
                <label>Figure 3.</label>
                <caption>
                  <p>Schematic representation depicting adjuvant bisphosphonates recommended treatment algorithm based on MAF test .</p>
                </caption>
                <graphic xlink:href="pkab054f3" position="float"/>
              </fig>
            </sec>
            <sec>
              <title>Funding</title>
              <p>This work was supported by the US National Cancer Institute, National Surgical Adjuvant Breast and Bowel Project, Inbiomotion and Bayer Oy (formerly Schering Oy), and grants from the U10CA180868 (NCI Cancer Trial Network), UG1CA189867 (NCI Community Oncology Research Program), U10CA180822 (NRG Oncology SDMC [Biostats]), U24CA196067-04 (BSB) (Lab).</p>
            </sec>
            <sec>
              <title>Footnotes</title>
              <p><bold>Role of the funders:</bold> The funders did not have a role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. </p>
              <p><bold>Disclosures:</bold> AB is consultant for Amgen, Novartis, Agendia. JJM owns less than 0.25% and JCT is an employee of Inbiomotion. RRG and JCT have patents pending related to this work. RRG declares shares of Inbiomotion (&lt;US$25 000). The other authors declare no competing interests.</p>
              <p><bold>Author contributions:</bold> AHGP: Principal Investigator, Conceptualization, Author. PCL: Investigator, Resources. SJA: Statistician, Resources, Editing. EPM: Resources, Supervision, Editing. AB: Investigator, Resources, Review. LB-D: Investigator, Resources, Review. KMK: Investigator, Resources, Review. TL: Investigator, Resources, Review. AR: Investigator, Resources, Review. JW: Investigator, Resources, Review. MF: Resources, project administration. MS: Statistician, Review JCT: Investigator, Data Curation, Editing. JJM: Funding acquisition, Conceptualization, Editing. ACW: Investigator, Resources, Review. LF: Investigator, Resources, Review. NW: Investigator, Resources, Review. RRG: Conceptualization, Investigator, Methodology, Author.</p>
              <p><bold>Acknowledgements:</bold> We thank members of the NSABP group, and all women participating in NSABP B-34. The original trial was supported by the National Cancer Institute’s Department of Health and Human Services public health service grants with additional funding from Bayer Oy (formerly Schering Oy).</p>
              <p><bold>Disclaimer:</bold> The US Department of Health and Human Services specifically disclaims responsibility for any analysis, interpretations, or conclusions; and Schering-Plough Inc. </p>
            </sec>
            <sec>
              <title>Data Availability </title>
              <p>All data published in this article and any related data will be available on request to the corresponding author.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>pkab054_Supplementary_Data</label>
                <media xlink:href="pkab054_supplementary_data.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="pkab054-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coleman</surname><given-names>RE</given-names></string-name>, <string-name><surname>Collinson</surname><given-names>M</given-names></string-name>, <string-name><surname>Gregory</surname><given-names>W</given-names></string-name></person-group>, <etal>et al</etal><article-title>Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)</article-title>. <source>J Bone Oncol</source>. <year>2018</year>;<volume>13</volume>:<fpage>123</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">30591866</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paterson</surname><given-names>AH</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lembersky</surname><given-names>BC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial</article-title>. <source>Lancet Oncol</source>. <year>2012</year>;<volume>13</volume>(<issue>7</issue>):<fpage>734</fpage>–<lpage>742</lpage>.<pub-id pub-id-type="pmid">22704583</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><collab>Early Breast Cancer Trials Collaborative Group</collab>. <article-title>Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>10001</issue>):<fpage>1353</fpage>–<lpage>1361</lpage>.<pub-id pub-id-type="pmid">26211824</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hadji</surname><given-names>P</given-names></string-name>, <string-name><surname>Coleman</surname><given-names>RE</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel</article-title>. <source>Ann Oncol</source>. <year>2016</year>;<volume>27</volume>(<issue>3</issue>):<fpage>379</fpage>–<lpage>390</lpage>.<pub-id pub-id-type="pmid">26681681</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dhesy-Thind</surname><given-names>S</given-names></string-name>, <string-name><surname>Fletcher</surname><given-names>GG</given-names></string-name>, <string-name><surname>Blanchette</surname><given-names>PS</given-names></string-name></person-group>, <etal>et al</etal><article-title>Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care Ontario and American Society of Clinical Oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>18</issue>):<fpage>2062</fpage>–<lpage>2081</lpage>.<pub-id pub-id-type="pmid">28618241</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coleman</surname><given-names>R</given-names></string-name>, <string-name><surname>Hall</surname><given-names>A</given-names></string-name>, <string-name><surname>Albanell</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial</article-title>. <source>Lancet Oncol</source>. <year>2017</year>;<volume>18</volume>(<issue>11</issue>):<fpage>1543</fpage>–<lpage>1552</lpage>.<pub-id pub-id-type="pmid">29037984</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coleman</surname><given-names>R</given-names></string-name>, <string-name><surname>Hadji</surname><given-names>P</given-names></string-name>, <string-name><surname>Body</surname><given-names>JJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>Bone health in cancer: ESMO Clinical Practice Guidelines</article-title>. <source>Ann Oncol</source>. <year>2020</year>;<volume>31</volume>(<issue>12)</issue>:<fpage>1650</fpage>–<lpage>1663</lpage>. doi:10.1016/j.annonc.2020.07.019.<pub-id pub-id-type="pmid">32801018</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brufsky</surname><given-names>A</given-names></string-name>, <string-name><surname>Mathew</surname><given-names>A.</given-names></string-name></person-group><article-title>Bisphosphonate choice as adjuvant therapy for breast cancer: does it matter?</article-title><source>J Natl Cancer Inst</source>. <year>2020</year>;<volume>112</volume>(<issue>7</issue>):<fpage>659</fpage>–<lpage>660</lpage>.<pub-id pub-id-type="pmid">31693134</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pavlovic</surname><given-names>M</given-names></string-name>, <string-name><surname>Arnal-Estape</surname><given-names>A</given-names></string-name>, <string-name><surname>Rojo</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Enhanced MAF oncogene expression and breast cancer bone metastasis</article-title>. <source>J Natl Cancer Inst</source>. <year>2015</year>;<volume>107</volume>(<issue>12</issue>):<fpage>djv256</fpage>.<pub-id pub-id-type="pmid">26376684</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lei</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhuang</surname><given-names>X</given-names></string-name></person-group>, <etal>et al</etal><article-title>DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>(<issue>4</issue>):<fpage>1646</fpage>–<lpage>1659</lpage>.<pub-id pub-id-type="pmid">24590291</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pascual</surname><given-names>G</given-names></string-name>, <string-name><surname>Avgustinova</surname><given-names>A</given-names></string-name>, <string-name><surname>Mejetta</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Targeting metastasis-initiating cells through the fatty acid receptor CD36</article-title>. <source>Nature</source>. <year>2017</year>;<volume>541</volume>(<issue>7635</issue>):<fpage>41</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">27974793</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salvador</surname><given-names>F</given-names></string-name>, <string-name><surname>Llorente</surname><given-names>A</given-names></string-name>, <string-name><surname>Gomis</surname><given-names>RR.</given-names></string-name></person-group><article-title>From latency to overt bone metastasis in breast cancer: potential for treatment and prevention</article-title>. <source>J Pathol</source>. <year>2019</year>;<volume>249</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">31095738</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simon</surname><given-names>RM</given-names></string-name>, <string-name><surname>Paik</surname><given-names>S</given-names></string-name>, <string-name><surname>Hayes</surname><given-names>DF.</given-names></string-name></person-group><article-title>Use of archived specimens in evaluation of prognostic and predictive biomarkers</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>(<issue>21</issue>):<fpage>1446</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">19815849</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coleman</surname><given-names>RE</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>H</given-names></string-name>, <string-name><surname>Cameron</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal><article-title>Breast-cancer adjuvant therapy with zoledronic acid</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>15</issue>):<fpage>1396</fpage>–<lpage>1405</lpage>.<pub-id pub-id-type="pmid">21995387</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Lin</surname><given-names>DY</given-names></string-name>, <string-name><surname>Weissfeld</surname><given-names>L.</given-names></string-name></person-group><article-title>Regression analysis of multivariate incomplete failure time data by modeling marginal distribution</article-title>. <source>J Am Stat Assoc</source>. <year>1989</year>;<volume>84</volume>(<issue>408</issue>):<fpage>1065</fpage>–<lpage>1073</lpage>.</mixed-citation>
              </ref>
              <ref id="pkab054-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paterson</surname><given-names>AH</given-names></string-name>, <string-name><surname>Powles</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Kanis</surname><given-names>JA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer</article-title>. <source>J Clin Oncol</source>. <year>1993</year>;<volume>11</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">8418243</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roelofs</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>K</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Molecular mechanisms of action of bisphosphonates: current status</article-title>. <source>Clin Cancer Res</source>. <year>2006</year>;<volume>12</volume>(<issue>20, pt 2</issue>):<fpage>6222s</fpage>–<lpage>6230s</lpage>.<pub-id pub-id-type="pmid">17062705</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gralow</surname><given-names>JR</given-names></string-name>, <string-name><surname>Barlow</surname><given-names>WE</given-names></string-name>, <string-name><surname>Paterson</surname><given-names>AHG</given-names></string-name></person-group>, <etal>et al</etal><article-title>Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307</article-title>. <source>J Natl Cancer Inst</source>. <year>2019</year>;<volume>112</volume>(<issue>7</issue>):<fpage>698</fpage>–<lpage>707</lpage>. doi:10.1093/jnci/djz215.</mixed-citation>
              </ref>
              <ref id="pkab054-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diel</surname><given-names>IJ</given-names></string-name>, <string-name><surname>Solomayer</surname><given-names>EF</given-names></string-name>, <string-name><surname>Costa</surname><given-names>SD</given-names></string-name></person-group>, <etal>et al</etal><article-title>Reduction in new metastases in breast cancer with adjuvant clodronate treatment</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>339</volume>(<issue>6</issue>):<fpage>357</fpage>–<lpage>363</lpage>.<pub-id pub-id-type="pmid">9691101</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name><surname>Paterson</surname><given-names>A</given-names></string-name>, <string-name><surname>McCloskey</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal><article-title>Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]</article-title>. <source>Breast Cancer Res</source>. <year>2006</year>;<volume>8</volume>(<issue>2</issue>):<fpage>R13</fpage>.<pub-id pub-id-type="pmid">16542503</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saarto</surname><given-names>T</given-names></string-name>, <string-name><surname>Vehmanen</surname><given-names>L</given-names></string-name>, <string-name><surname>Virkkunen</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal><article-title>Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients</article-title>. <source>Acta Oncol</source>. <year>2004</year>;<volume>43</volume>(<issue>7</issue>):<fpage>650</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">15545185</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gnant</surname><given-names>M.</given-names></string-name></person-group><article-title>Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?</article-title><source>Curr Oncol Rep</source>. <year>2012</year>;<volume>14</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">22113793</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>von Minckwitz</surname><given-names>G</given-names></string-name>, <string-name><surname>Procter</surname><given-names>M</given-names></string-name>, <string-name><surname>de Azambuja</surname><given-names>E</given-names></string-name></person-group>, <etal>et al</etal>; for the <collab>APHINITY Steering Committee and Investigators</collab>. <article-title>Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>2</issue>):<fpage>122</fpage>–<lpage>131</lpage>.<pub-id pub-id-type="pmid">28581356</pub-id></mixed-citation>
              </ref>
              <ref id="pkab054-B24">
                <label>24</label>
                <mixed-citation publication-type="other"><collab>National Institute for Health and Care Excellence. Early breast cancer preventing recurrence and improving survival: Adjuvant bisphosphonates evidence summary;</collab> July <year>2017</year>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
